SI2727588T1 - Na baklofenu in akamprosatu temelječa terapija nevroloških motenj - Google Patents

Na baklofenu in akamprosatu temelječa terapija nevroloških motenj

Info

Publication number
SI2727588T1
SI2727588T1 SI201231471T SI201231471T SI2727588T1 SI 2727588 T1 SI2727588 T1 SI 2727588T1 SI 201231471 T SI201231471 T SI 201231471T SI 201231471 T SI201231471 T SI 201231471T SI 2727588 T1 SI2727588 T1 SI 2727588T1
Authority
SI
Slovenia
Prior art keywords
baclofen
neurological disorders
based therapy
acamprosate
acamprosate based
Prior art date
Application number
SI201231471T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Emmanuel Vial
Mickael Guedj
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of SI2727588T1 publication Critical patent/SI2727588T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201231471T 2011-03-01 2012-03-01 Na baklofenu in akamprosatu temelječa terapija nevroloških motenj SI2727588T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305217 2011-03-01
US201161468658P 2011-03-29 2011-03-29
US201161493606P 2011-06-06 2011-06-06
EP11305687 2011-06-06
EP13196461.1A EP2727588B1 (en) 2011-03-01 2012-03-01 Baclofen and acamprosate based therapy of neurological disorders

Publications (1)

Publication Number Publication Date
SI2727588T1 true SI2727588T1 (sl) 2019-03-29

Family

ID=46758335

Family Applications (3)

Application Number Title Priority Date Filing Date
SI201230019T SI2560631T1 (sl) 2011-03-01 2012-03-01 Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
SI201231317T SI2796132T1 (sl) 2011-03-01 2012-03-01 Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu
SI201231471T SI2727588T1 (sl) 2011-03-01 2012-03-01 Na baklofenu in akamprosatu temelječa terapija nevroloških motenj

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SI201230019T SI2560631T1 (sl) 2011-03-01 2012-03-01 Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti
SI201231317T SI2796132T1 (sl) 2011-03-01 2012-03-01 Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu

Country Status (27)

Country Link
US (7) US9820978B2 (sl)
EP (5) EP2727588B1 (sl)
JP (2) JP5987008B2 (sl)
KR (2) KR101918745B1 (sl)
CN (2) CN103596562B (sl)
AU (2) AU2012222351B2 (sl)
BR (1) BR112013022112B1 (sl)
CA (1) CA2828765C (sl)
CY (3) CY1115074T1 (sl)
DK (3) DK2727588T3 (sl)
EA (2) EA023277B1 (sl)
ES (5) ES2698927T3 (sl)
HK (2) HK1182615A1 (sl)
HR (1) HRP20140131T1 (sl)
HU (1) HUE038653T2 (sl)
IL (2) IL228177B (sl)
LT (2) LT2727588T (sl)
MX (1) MX340568B (sl)
PL (3) PL2560631T3 (sl)
PT (1) PT2560631E (sl)
RS (3) RS58114B1 (sl)
SG (2) SG192968A1 (sl)
SI (3) SI2560631T1 (sl)
SM (1) SMT201400029B (sl)
TR (1) TR201809351T4 (sl)
WO (2) WO2012117075A2 (sl)
ZA (1) ZA201306039B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
PL2560631T3 (pl) 2011-03-01 2014-06-30 Pharnext Terapia zaburzeń neurologicznych oparta na baklofenie i akamprozacie
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
UA115968C2 (uk) * 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
CN108057033A (zh) * 2011-03-01 2018-05-22 法耐斯特公司 用于治疗肌萎缩性侧索硬化症的新组合物
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
GB2501457A (en) 2012-02-10 2013-10-30 Rational Intellectual Holdings Ltd Assigning player positions in an online table game
AU2013224959B2 (en) * 2012-03-01 2017-12-07 Pharnext New compositions for treating amyotrophic lateral sclerosis
US9545389B2 (en) * 2012-07-18 2017-01-17 Pharnext Baclofen and acamprosate based therapy of macular degeneration disorders
EP2705841A1 (en) * 2012-09-05 2014-03-12 Pharnext Combinations of nootropic agents for treating cognitive dysfunctions
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
UA114811C2 (uk) * 2013-02-28 2017-08-10 Фарнекст Застосування акампросату та баклофену для лікування аміотрофічного бічного склерозу
BR112015030268B1 (pt) 2013-06-05 2023-01-31 Pharnext Composição farmacêutica
JP6476174B2 (ja) 2013-06-19 2019-02-27 ソム イノヴェーション バイオテック、ソシエダッド リミターダ 運動過剰障害の予防および／または治療における使用のための治療剤
KR102206745B1 (ko) * 2013-07-12 2021-02-03 경상대학교산학협력단 안토시아닌 및 gabab 수용체 작용제를 유효성분으로 포함하는 신경질환 치료제
WO2015023830A1 (en) 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
WO2015063140A1 (en) * 2013-10-30 2015-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EA201691602A1 (ru) * 2014-02-11 2017-03-31 Фарнекст Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
WO2016081472A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
EP3291800A4 (en) 2015-05-04 2018-09-26 Confluence Pharmaceuticals, LLC Sprinkle formulations of acamprosate
EP3156050A1 (en) * 2015-10-16 2017-04-19 Universitat Autònoma De Barcelona New combination therapies for treating neurological damage
ES2894801T3 (es) 2015-12-29 2022-02-15 Univ Kyoto Agente para prevenir y/o tratar la enfermedad de Alzheimer
JP7027318B2 (ja) * 2016-02-05 2022-03-01 ファーネクスト 神経障害の新規の併用療法
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
AU2018258970B2 (en) * 2017-04-24 2021-07-15 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
KR20200005576A (ko) * 2017-05-17 2020-01-15 컨플루언스 파마슈티컬스, 엘엘씨 호모타우린 및 이의 염의 제형
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of ***e use or in preventing relapse into ***e use
CN111902138A (zh) * 2018-01-29 2020-11-06 法奈克斯公司 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗
CN116059192A (zh) 2019-11-13 2023-05-05 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US6573251B2 (en) 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
AU3173301A (en) 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
PL367417A1 (en) 2001-07-19 2005-02-21 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
WO2003080068A1 (en) 2002-03-18 2003-10-02 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
EP1563846B1 (en) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
KR101140559B1 (ko) 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
CA2551859C (en) 2003-12-30 2011-10-04 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2006059777A1 (ja) 2004-11-30 2006-06-08 Angesmg, Inc. アルツハイマー治療剤
US20080188510A1 (en) 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CA2655029A1 (en) 2006-07-06 2008-01-10 Roskamp Research, Llc Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
US20080206332A1 (en) 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
PL2157973T3 (pl) 2007-05-22 2015-12-31 Otsuka Pharma Co Ltd Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
WO2009033061A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en) 2007-10-15 2009-08-01 Xenoport Inc Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009061934A1 (en) 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
NZ589304A (en) * 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
EA019571B1 (ru) 2008-04-29 2014-04-30 Фарнекст Применение сульфизоксазола для лечения болезни альцгеймера
MX2010011881A (es) * 2008-04-29 2011-07-01 Pharnext Nuevos enfoques terapeuticos para tratar la enfermedad de alzheimer y trastornos relacionados mediante una modulacion de la angiogenesis.
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9273050B2 (en) 2008-11-27 2016-03-01 National University Corporation Kagawa University Cyclobutyl purine derivative, angiogenesis promoting agent, lumen formation promoting agent, neurocyte growth promoting agent, and drug
CA2745741A1 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
CN102341099A (zh) 2009-03-03 2012-02-01 什诺波特有限公司 R-巴氯芬前药的持续释放口服剂型
WO2010120370A2 (en) 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US9387206B2 (en) 2009-11-03 2016-07-12 Pharnext Therapeutic approaches for treating Alzheimer's disease
US9867837B2 (en) 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
PL2560631T3 (pl) 2011-03-01 2014-06-30 Pharnext Terapia zaburzeń neurologicznych oparta na baklofenie i akamprozacie
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders

Also Published As

Publication number Publication date
US9144558B2 (en) 2015-09-29
SI2796132T1 (sl) 2018-09-28
BR112013022112B1 (pt) 2021-09-28
KR101918745B1 (ko) 2018-11-15
CA2828765A1 (en) 2012-09-07
MX2013010043A (es) 2014-02-11
AU2017210501B2 (en) 2018-11-01
EA023277B1 (ru) 2016-05-31
CY1120925T1 (el) 2019-12-11
SG10201610587SA (en) 2017-02-27
JP5987008B2 (ja) 2016-09-06
JP2014510069A (ja) 2014-04-24
CN103596562B (zh) 2016-06-01
KR20140038378A (ko) 2014-03-28
BR112013022112A2 (pt) 2018-06-26
ES2845204T3 (es) 2021-07-26
CN105997969B (zh) 2022-03-25
HK1203158A1 (en) 2015-10-23
EP3332781A1 (en) 2018-06-13
US20140080873A1 (en) 2014-03-20
US20130090307A1 (en) 2013-04-11
ES2450074T3 (es) 2014-03-21
KR20180043844A (ko) 2018-04-30
US20170231958A1 (en) 2017-08-17
EA201891833A1 (ru) 2019-01-31
WO2012117075A3 (en) 2012-12-13
RS58114B1 (sr) 2019-02-28
WO2012117076A3 (en) 2012-10-26
IL228177B (en) 2018-01-31
SI2560631T1 (sl) 2014-06-30
HRP20140131T1 (hr) 2014-05-09
NZ614184A (en) 2015-08-28
AU2012222351A1 (en) 2013-08-29
EA201300974A1 (ru) 2014-01-30
EP2560631B1 (en) 2014-01-15
SMT201400029B (it) 2014-07-07
DK2727588T3 (en) 2018-12-10
AU2017210501A1 (en) 2017-08-17
LT2727588T (lt) 2019-01-25
US20140378440A1 (en) 2014-12-25
PL2560631T3 (pl) 2014-06-30
HUE038653T2 (hu) 2018-11-28
EP2796132A1 (en) 2014-10-29
PT2560631E (pt) 2014-02-24
JP2017193562A (ja) 2017-10-26
CY1115074T1 (el) 2016-12-14
US20160000736A1 (en) 2016-01-07
US20200085790A1 (en) 2020-03-19
WO2012117075A2 (en) 2012-09-07
ES2665569T3 (es) 2018-04-26
KR101937782B1 (ko) 2019-01-11
TR201809351T4 (tr) 2018-07-23
IL261725A (en) 2018-10-31
US8865769B2 (en) 2014-10-21
RS53227B (en) 2014-08-29
WO2012117076A2 (en) 2012-09-07
CN105997969A (zh) 2016-10-12
EP2727588B1 (en) 2018-08-29
SG192968A1 (en) 2013-09-30
ES2678794T3 (es) 2018-08-17
AU2012222351B2 (en) 2017-05-18
CY1120369T1 (el) 2019-07-10
PL2796132T3 (pl) 2018-10-31
ZA201306039B (en) 2014-10-29
ES2698927T3 (es) 2019-02-06
EP2560631A2 (en) 2013-02-27
US20130085122A1 (en) 2013-04-04
US9636316B2 (en) 2017-05-02
RS57426B1 (sr) 2018-09-28
JP6416328B2 (ja) 2018-10-31
US9820978B2 (en) 2017-11-21
EP2680835B1 (en) 2018-02-07
LT2796132T (lt) 2018-10-10
DK2796132T3 (en) 2018-07-23
CN103596562A (zh) 2014-02-19
PL2727588T3 (pl) 2019-04-30
US8741886B2 (en) 2014-06-03
EP2796132B1 (en) 2018-05-02
EP2727588A1 (en) 2014-05-07
CA2828765C (en) 2019-07-30
MX340568B (es) 2016-07-14
HK1182615A1 (en) 2013-12-06
DK2560631T3 (da) 2014-02-10
EP2680835A2 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
HK1203158A1 (en) Baclofen and acamprosate based therapy of neurological disorders
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
HK1214832A1 (zh) 用於代謝病症和疾病治療的組合物和方法
ZA201308421B (en) Compositions uses and methods for treatment of metabolic disorders and diseases
ZA201205829B (en) Treatment of respiratory disorders
IL225896A0 (en) Treatment of mecp-2 related disorders
IL229705A0 (en) Methods for the treatment or prevention of neurological diseases
EP2681209A4 (en) COMPOUNDS AND METHODS FOR TREATING PAIN AND OTHER DISEASES
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
HK1209335A1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
EP2723325A4 (en) NEW FORMULATIONS AND METHODS FOR TREATING DERMATOLOGICAL DISORDERS OR DISEASES
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2800554A4 (en) METHOD FOR TREATING MULTIPLE SCLEROSIS AND OTHER DEMYELINISING DISEASES
GB201107467D0 (en) Novel treatment of pain
HRP20181945T1 (hr) Liječenje neuroloških poremećaja na bazi baklofena i akamprozata
GB201001912D0 (en) Treatment of respiratory disorders
AU2011902407A0 (en) Treatment of pain
GB201101773D0 (en) Treatment of inflammatory disorders